Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer




+44 (0)20 3313 3759eric.aboagye




Mrs Maureen Francis +44 (0)20 7594 2793




GN1Commonwealth BuildingHammersmith Campus






BibTex format

author = {Allott, L and Aboagye, EO},
doi = {10.1021/acs.molpharmaceut.0c00328},
journal = {Molecular Pharmaceutics},
pages = {2245--2259},
title = {Chemistry considerations for the clinical translation of oncology PET radiopharmaceuticals},
url = {},
volume = {17},
year = {2020}

RIS format (EndNote, RefMan)

AB - Positron emission tomography (PET) has proven to be an invaluable tool in the staging and management of disease in oncology; however, [18F]fluorodeoxyglucose ([18F]FDG) remains the most widely used PET radiopharmaceutical despite the large financial investment in novel radiotracer development. We report our perspective and experience of translating radiopharmaceuticals into clinical studies, discussing the PET development pipeline from a chemistry perspective. We hope that, by identifying potential points of attrition along the pipeline and suggesting solutions to these problems, we may help others take their preclinical radiotracers into human studies. This review focuses primarily on the development of fluorine-18 radiopharmaceuticals, although the broader field of radiometal chemistry is considered where the translation journey is similar.
AU - Allott,L
AU - Aboagye,EO
DO - 10.1021/acs.molpharmaceut.0c00328
EP - 2259
PY - 2020///
SN - 1543-8384
SP - 2245
TI - Chemistry considerations for the clinical translation of oncology PET radiopharmaceuticals
T2 - Molecular Pharmaceutics
UR -
UR -
UR -
UR -
VL - 17
ER -